This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kollmannsberger, C. Articles by Bokemeyer, C. Search for Related Content PubMed PubMed Citation Articles by Kollmannsberger, C. Articles by Bokemeyer, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Testicular Cancer Testicular Disorders Social Bookmarking                            What's this?

Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group

From the Department of Hematology/Oncology, University of Tuebingen Medical Center, Tuebingen; Department of Hematology/Oncology, University of Marburg, Marburg; Department of Hematology/Oncology, University of Muenster, Muenster; Department of Hematology/Oncology, University of Hannover Medical School, Hannover; Department of Hematology/Oncology, Klinikum Oldenburg, Oldenburg; Department of Hematology/Oncology, Charite, University of Berlin, Berlin; Department of Hematology/Oncology, Hegau-Klinikum, Singen; and Department of Hematology/Oncology, University of Goettingen, Goettingen, Germany

Address reprint requests to C. Bokemeyer, MD, Department of Hematology/Oncology, University of Tuebingen Medical Center, Otfried-Mueller-Str 10, 72076 Tuebingen, Germany; e-mail: carsten.bokemeyer{at}med.uni-tuebingen.de

PURPOSE: Long-term survival is rarely achieved in patients with cisplatin-refractory germ cell cancer (GCT). Both single-agent gemcitabine and oxaliplatin have shown activity in patients who experience relapse or are refractory to cisplatin treatment. This study investigates the activity of a gemcitabine plus oxaliplatin regimen in these patients.

PATIENTS AND METHODS: Gemcitabine was administered at a dose of 1,000 mg/m² on days 1 and 8; oxaliplatin was administered at a dose of 130 mg/m² on day 1. Response was evaluated every 4 weeks.

RESULTS: Thirty-five patients with a median age of 37 years (range, 21 to 54 years) were enrolled onto the study. Primary tumor localization was gonadal, retroperitoneal, or mediastinal in 30, one, and four patients, respectively. Patients had been pretreated with a median of six platinum-containing cycles (range, four to 13 cycles) and 89% of patients previously had experienced treatment failure after high-dose chemotherapy with peripheral-blood stem-cell transplantation. Sixty-three percent of patients were considered absolutely cisplatin-refractory or cisplatin-refractory. A median of two cycles (range, 1 to 6 cycles) per patient were applied. Toxicity consisted mainly of myelosuppression, with Common Toxicity Criteria grade 3 occurring in 54% of patients. Only 9% of patients developed neutropenic fever. Three patients attained a complete remission (CR), two patients attained a marker-negative partial remission, and 11 patients attained a marker-positive partial remission, resulting in an overall response rate of 46% (95% CI, 30% to 64%). All three patients with CR and one patient with a marker-negative partial remission remained disease free at 16+, 12+, 4+, and 2+ months of follow-up. Seven (44%) of these 16 responses, including one CR, occurred in cisplatin-refractory patients.

CONCLUSION: Gemcitabine plus oxaliplatin demonstrates antitumor activity with acceptable toxicity in heavily pretreated patients with relapsed or cisplatin-refractory GCT, and may offer a chance of long-term survival for selected patients.

Supported by an educational grant from Sanofi-Synthelabo Inc, Berlin, Germany.

These data were presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology Meeting, Chicago, IL, May 31-June 3, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Theodore, C. Chevreau, Y. Yataqhene, K. Fizazi, J. -P. Delord, J. -P. Lotz, L. Geoffrois, P. Kerbrat, V. Bui, and A. Flechon A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors Ann. Onc., August 1, 2008; 19(8): 1465 - 1469. [Abstract] [Full Text] [PDF]

				A. Necchi, N. Nicolai, and R. Salvioni Does oxaliplatin and paclitaxel combination show an activity of some extent in pretreated patients with germ-cell tumors?: Reply to the article "A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors" by C. Theodore et al. (Ann Oncol 2008; doi: 10.1093/annonc/mdn122) Ann. Onc., August 1, 2008; 19(8): 1509 - 1509. [Full Text] [PDF]

				C. Bokemeyer, K. Oechsle, F. Honecker, F. Mayer, J. T. Hartmann, C. F. Waller, I. Bohlke, and C. Kollmannsberger Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group Ann. Onc., March 1, 2008; 19(3): 448 - 453. [Abstract] [Full Text] [PDF]

				D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]

				O. Khan and A. Protheroe Testis cancer Postgrad. Med. J., October 1, 2007; 83(984): 624 - 632. [Abstract] [Full Text] [PDF]

				T El Gnaoui, J Dupuis, K Belhadj, J-P Jais, A Rahmouni, C Copie-Bergman, I Gaillard, M Divine, I Tabah-Fisch, F Reyes, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy Ann. Onc., August 1, 2007; 18(8): 1363 - 1368. [Abstract] [Full Text] [PDF]

				J Shamash, T Powles, K Mutsvangwa, P Wilson, W Ansell, E Walsh, D Berney, J Stebbing, and T Oliver A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours Ann. Onc., May 1, 2007; 18(5): 925 - 930. [Abstract] [Full Text] [PDF]

				L. H. Einhorn, M. J. Brames, B. Juliar, and S. D. Williams Phase II Study of Paclitaxel Plus Gemcitabine Salvage Chemotherapy for Germ Cell Tumors After Progression Following High-Dose Chemotherapy With Tandem Transplant J. Clin. Oncol., February 10, 2007; 25(5): 513 - 516. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta and R. J. Motzer Chemotherapy for Advanced Germ Cell Tumors J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502. [Abstract] [Full Text] [PDF]

				P. M. Bedano, M. J. Brames, S. D. Williams, B. E. Juliar, and L. H. Einhorn Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors J. Clin. Oncol., December 1, 2006; 24(34): 5403 - 5407. [Abstract] [Full Text] [PDF]

				R. Manon, A. O'Neill, J. Knisely, M. Werner-Wasik, H. M. Lazarus, H. Wagner, M. Gilbert, and M. Mehta Phase II Trial of Radiosurgery for One to Three Newly Diagnosed Brain Metastases From Renal Cell Carcinoma, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397) J. Clin. Oncol., December 1, 2005; 23(34): 8870 - 8876. [Abstract] [Full Text] [PDF]

				O. Rick, C. Bokemeyer, S. Weinknecht, J. Schirren, T. Pottek, J.T. Hartmann, T. Braun, B. Rachud, L. Weissbach, M. Hartmann, et al. Residual Tumor Resection After High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Cancer J. Clin. Oncol., September 15, 2004; 22(18): 3713 - 3719. [Abstract] [Full Text] [PDF]

				K. Fizazi, S. Culine, and I. Chen Oxaliplatin in non-seminomatous germ-cell tumors Ann. Onc., August 1, 2004; 15(8): 1295 - 1295. [Full Text] [PDF]